Emily Voigt

Associate Professor

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Emily Voigt is an Associate Professor at the Oregon Health & Science University Vaccine and Gene Therapy Institute in the United States. Her research focuses on innovative vaccine technologies, including spray-dried replicon vaccines and self-amplifying RNA vaccines targeting various viral infections such as COVID-19, yellow fever, and Zika. She has authored several recent articles addressing vaccine development strategies and immune response optimization.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Christopher B. Fox

Associate Dean of Research

Utah State University

UNITED STATES

View details

Konstantin MJ Sparrer

Ulm University

GERMANY

View details

David Gordon

Assistant Professor

Emory University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emily Voigt

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A spray dried replicon vaccine platform for pandemic response.

A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses.

Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission.

Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.

Exploring yeast glucans for vaccine enhancement: Sustainable strategies for overcoming adjuvant challenges in a SARS-CoV-2 model

Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques.

Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus.

Collaborators (3)

Christopher B. Fox

Konstantin MJ Sparrer

David Gordon

Make your next move.